FASEB Summer Research Conference on Lysophospholipid Mediators in Health & Diseas

描述（由申请人提供）：会议目标：2005年会议的重点是确定溶血脂质信号传导的生理学、病理生理学和治疗重要性的综合方法，而2007年生物活性溶血脂质会议则更多地关注最近的发展，这些发展开始显示靶向溶血脂质信号传导的治疗重要性。 汇集学生，博士后，初级科学家和高级研究人员，他们对不同学科的生物活性溶血脂感兴趣。基因组学和蛋白质组学的成熟为理解代谢、信号转导途径和溶解脂质介质的功能提供了新的工具。此外，许多重要受体和溶血脂质代谢酶的敲除小鼠的研究以及开发溶血脂质定向治疗的最新进展为回答广泛的生物学和临床问题提供了新的方法。通过将研究人员聚集在一起，我们的会议将通过将注意力集中在最紧迫的问题上并突出研究溶血脂质信号的不同方法来提高该领域科学发现的速度。 促进分享未发表的研究观察结果：溶血脂质研究进展非常快，在实验室发现的时间与科学界可获得的同行评审研究出版物中的描述之间往往存在很大的滞后。像这样一个重点突出的科学会议是传播新成果的最佳机制之一。这次会议的合议气氛和充分的互动机会为分享新的和未发表的意见提供了一个很好的论坛。 确定研究生物活性溶血脂的新途径和方法：生物活性溶血脂独特的结构和理化性质意味着需要专门的技术进行检测，定量，成像和分析。这些包括发展复杂的质谱分析和使用新的荧光探针来监测细胞和组织中的溶解脂质形成和运输。会议的特点是在这些领域具有特殊专长的研究人员的介绍。 促进新的合作：许多新的试剂和分子和生物信息学工具继续开发，本次会议促进的相互作用将促进这些试剂和工具的共享。这将大大加快研究进程。研究人员之间的想法、工具和试剂的共享也可以促进重要的新合作的发展。 确定新的治疗相关性：免疫抑制药物FTY 720作为S1 P受体激动剂的作用机制的阐明以及靶向LPA和S1 P受体和信号传导的实验疗法的开发进展使溶血脂质信号传导成为药物发现的最前沿，因为当今市场上的大多数药物都是针对G蛋白偶联受体的。基础科学家、药理学家、化学家和对临床和临床前研究感兴趣的研究人员之间的相互作用肯定会导致溶血脂质信号与疾病之间新的治疗相关性。 促进毕业生和研究生学员以及初级调查员的职业发展，特别强调妇女、少数民族和残疾人：教育和职业发展是本次会议的首要目标，为毕业生和研究生学员提供了一个独特的机会，与实地的既定调查员进行个人互动。正在为受训人员提供许多机会，使他们能够在一种支持性但具有批判性的气氛中介绍和讨论他们的研究。大部分资金筹集的目的是支持年轻科学家以及妇女，少数民族和残疾人的出席。如下文所述，会议有一个强大的传统，即以初级和初级调查人员为发言人，我们有一个完善的计划，以促进妇女和少数民族调查人员参与这次会议的各个方面。

DESCRIPTION (provided by applicant): Conference Objectives: Whereas the emphasis of the 2005 conference was on integrated approaches towards defining the physiological, pathophysiological and therapeutic importance of lysolipid signaling, the 2007 Conference on Bioactive Lysolipids is focused more on recent developments that are beginning to show the therapeutic importance of targeting lysolipid signaling. To bring together students, postdoctoral, junior scientists, and senior investigators with an interest in bioactive lysolipids who work in diverse disciplines. The maturation of genomics and proteomics have provided new tools for understanding metabolism, signal transduction pathways, and functions of lysolipid mediators. Moreover, the study of knockout mice for many of the important receptors and lysolipid metabolic enzymes and recent progress in developing lysolipid-directed therapeutics has provided new approaches to answer a broad range of biological and clinical questions. By bringing researchers together, our conference will increase the speed of scientific discovery in the field by focusing attention on the most pressing issues and highlighting different approaches to studying lysolipid signaling. To promote sharing of unpublished research observations: Lysolipid research is moving extremely fast and there is often a substantial lag between the time discoveries are made at the bench and their description in a peer reviewed research publication that is available to the scientific community. A focused scientific conference such as this is one of the best mechanisms for dissemination of new results. The collegial atmosphere of this conference and the ample opportunities for interaction provide an excellent forum for sharing new and unpublished observations. To identify novel approaches and methods for studying bioactive lysolipids: The unique structural and physicochemical properties of bioactive lysolipids means that specialized techniques are required for their detection, quantitation, imaging and analysis. These include the development of sophisticated mass spectrometry-based analyses and the use of novel fluorescent probes to monitor lysolipid formation and trafficking in cells and tissues. The meeting features presentations from researchers with particular expertise in these areas. To promote new collaborations: Many new reagents and molecular and bioinformatic tools continue to be developed and interactions promoted by this conference will facilitate sharing of these reagents and tools. This will greatly accelerate research progress. Sharing of ideas, tools and reagents between researchers also can catalyze the development of important new collaborations. To identify new therapeutic correlations: The elucidation of the mechanism of action of the immunosuppressant drug FTY720 as a S1P receptor agonist and progress in the development of experimental therapeutics that target LPA and S1P receptors and signaling have put lysolipid signaling at the forefront of drug discovery since a majority of drugs on the market today are targeted toward G proteincoupled receptors. Interactions between basic scientists, pharmacologists, chemists and researchers with interests in clinical and preclinical research promise will surely lead to new therapeutic correlations between lysolipid signaling and disease. To foster the career development of graduate and postgraduate trainees and junior investigators with special emphasis on women, minorities and persons with disabilities: Education and career development is an overarching goal of this conference which provides a unique opportunity for graduate and postgraduate trainees to interact personally with established investigators in the field. Many opportunities are being provided for trainees to present and discuss their research in a supportive but critical atmosphere. Much of the fund raising is aimed at supporting the attendance of younger scientists as well as women, minorities, and disabled persons. As detailed below, the conference has a strong tradition of featuring beginning and junior investigators as speakers and we have a well-developed plan to promote the participation of women and minority investigators in every aspect of this meeting.